New hope for throat cancer patients: immunotherapy trial aims to keep cancer at bay
NCT ID NCT04910347
Summary
This study is testing whether adding the immunotherapy drug nivolumab after standard chemoradiation treatment can help prevent cancer from returning in patients with locally advanced nasopharyngeal carcinoma (a type of throat cancer). The trial will enroll 57 adults who have completed initial treatment but may still have residual disease. Participants will receive nivolumab infusions every three weeks for up to one year to see if it improves long-term cancer control.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yonsei University Health System, Severance Hospital
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.